Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
05:05:00 EDT Sun 13 Jul 2025
Enter Symbol
or Name
USA
CA



Z:PFE - PFIZER INC - https://www.pfizer.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PFE - Z4.025.65·25.665.025.65-0.135-0.534,853.1876,37262,13925.65  25.715  25.4231.54  20.91519:59:49Jul 1015 min RT 2¢

Recent Trades - Last 10 of 62139
Time ETExPriceChangeVolume
19:59:49Z25.66-0.125
19:59:39Z25.66-0.127
19:59:32Z25.645-0.1351
19:58:16Z25.68-0.104
19:57:57Z25.66-0.12200
19:57:15Z25.6999-0.080110
19:57:01Z25.6604-0.11962
19:56:46Z25.6606-0.11942
19:56:15Z25.6614-0.11861,041
19:53:46Z25.67-0.11100

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-07-10 06:45U:PFENews ReleaseXTANDI(TM) Plus Leuprolide Significantly Improves Survival Outcomes in Men with Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence
2025-06-26 06:45U:PFENews ReleasePfizer Announces Positive Topline Phase 3 Results for HYMPAVZI(TM) in Hemophilia A or B with Inhibitors
2025-06-25 17:30U:PFENews ReleasePfizer Declares Third-Quarter 2025 Dividend
2025-06-25 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts
2025-06-06 07:00U:PFENews ReleaseArvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer
2025-06-02 10:00U:PFENews ReleasePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
2025-05-31 08:01U:PFENews ReleaseArvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
2025-05-30 08:00U:PFENews ReleasePfizer's BRAFTOVI(TM) Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
2025-05-22 17:00U:PFENews ReleaseAstellas and Pfizer's XTANDI(TM) (enzalutamide) Shows Long-Term Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
2025-05-19 20:00U:PFENews ReleasePfizer Enters into Exclusive Licensing Agreement with 3SBio
2025-04-29 06:45U:PFENews ReleasePfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance
2025-04-26 13:30U:PFENews ReleasePfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naive, High-Risk Non-Muscle Invasive Bladder Cancer
2025-04-23 16:40U:PFENews ReleasePfizer Declares Second-Quarter 2025 Dividend
2025-04-23 15:46U:PFENews ReleasePfizer Advances Bold Vision for Future of Cancer Care at the ASCO 2025 Annual Meeting
2025-04-16 16:15U:PFENews ReleaseACIP Votes to Expand Recommendation for Pfizer's RSV Vaccine ABRYSVO(TM) to Include Adults Aged 50 to 59 at Increased Risk of Disease
2025-04-14 06:45U:PFENews ReleasePfizer Provides Update on Oral GLP-1 Receptor Agonist Danuglipron
2025-04-10 11:00U:PFENews ReleasePfizer Invites Shareholders to Attend Virtual 2025 Annual Meeting of Shareholders on April 24
2025-04-01 03:00U:PFENews ReleaseEuropean Commission Approves Pfizer's RSV Vaccine ABRYSVO(TM) to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
2025-03-26 09:01U:PFENews ReleaseViiV Healthcare Announces Reimbursement for APRETUDE for HIV-1 Pre-Exposure Prophylaxis (PrEP) under the Non-Insured Health Benefits (NIHB) Program
2025-03-18 10:00U:PFENews ReleasePfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts